{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:04:20Z","timestamp":1791572660770,"version":"4.3.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["5T32 HS000032-28"],"award-info":[{"award-number":["5T32 HS000032-28"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Financial relationships between physicians and the pharmaceutical industry are common, but factors that may determine whether such relationships result in physician practice changes are unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We evaluated physician use of orally administered cancer drugs for four cancers: prostate (abiraterone, enzalutamide), renal cell (axitinib, everolimus, pazopanib, sorafenib, sunitinib), lung (afatinib, erlotinib), and chronic myeloid leukemia (CML; dasatinib, imatinib, nilotinib). Separate physician cohorts were defined for each cancer type by prescribing history. The primary exposure was the number of calendar years during 2013\u20132015 in which a physician received payments from the manufacturer of one of the studied drugs; the outcome was relative prescribing of that drug in 2015, compared with the other drugs for that cancer. We evaluated whether practice setting at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, receipt of payments for purposes other than education or research (compensation payments), maximum annual dollar value received, and institutional conflict-of-interest policies were associated with the strength of the payment-prescribing association. We used modified Poisson regression to control confounding by other physician characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Physicians who received payments for a drug in all 3 years had increased prescribing of that drug (compared with 0 years), for renal cell (relative risk [RR] 1.81, 95% confidence interval [CI] 1.58\u20132.07), CML (RR 1.22, 95% CI 1.08\u20131.39), and lung (RR 1.69, 95% CI 1.58\u20131.82), but not prostate (RR 0.97, 95% CI 0.93\u20131.02). Physicians who received compensation payments or &amp;gt;$100 annually had increased prescribing compared with those who did not, but NCI setting and institutional conflict-of-interest policies were not consistently associated with the direction of prescribing change.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The association between industry payments and cancer drug prescribing was greatest among physicians who received payments consistently (within each calendar year). Receipt of payments for compensation purposes, such as for consulting or travel, and higher dollar value of payments were also associated with increased prescribing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0423","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T10:19:11Z","timestamp":1549448351000},"page":"632-639","source":"Crossref","is-referenced-by-count":46,"title":["Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology"],"prefix":"10.1093","volume":"24","author":[{"given":"Aaron P.","family":"Mitchell","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron N.","family":"Winn","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Medical College of Wisconsin, Milwaukee, Wisconsin, USA"},{"name":"Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Lund","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"},{"name":"Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie B.","family":"Dusetzina","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"},{"name":"Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"2021122506422246900_R1","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1056\/NEJMsa064508","article-title":"A national survey of physician-industry relationships","volume":"356","author":"Campbell","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122506422246900_R2","author":"CMS. The Facts About Open Payments Data","year":"2015"},{"key":"2021122506422246900_R3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cct.2012.05.011","article-title":"The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials","volume":"33","author":"Lerner","year":"2012","journal-title":"Contemp Clin Trials"},{"key":"2021122506422246900_R4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/JCO.2014.57.8898","article-title":"Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs","volume":"33","author":"Tibau","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122506422246900_R5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/jama.283.3.373","article-title":"Physicians and the pharmaceutical industry: Is a gift ever just a gift?","volume":"283","author":"Wazana","year":"2000","journal-title":"JAMA"},{"key":"2021122506422246900_R6","doi-asserted-by":"crossref","first-page":"e110130","DOI":"10.1371\/journal.pone.0110130","article-title":"Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits","volume":"9","author":"Lieb","year":"2014","journal-title":"PloS One"},{"key":"2021122506422246900_R7","doi-asserted-by":"crossref","first-page":"e1000352","DOI":"10.1371\/journal.pmed.1000352","article-title":"Information from pharmaceutical companies and the quality, quantity, and cost of physicians\u2019 prescribing: A systematic review","volume":"7","author":"Spurling","year":"2010","journal-title":"PLoS Med"},{"key":"2021122506422246900_R8","article-title":"Matching industry payments to medicare prescribing patterns: An analysis","author":"Jones","year":"2016","journal-title":"ProPublica"},{"key":"2021122506422246900_R9","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamainternmed.2016.2765","article-title":"Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries","volume":"176","author":"DeJong","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2021122506422246900_R10","doi-asserted-by":"crossref","first-page":"e0155474","DOI":"10.1371\/journal.pone.0155474","article-title":"Physician payments from industry are associated with greater Medicare Part D prescribing costs","volume":"11","author":"Perlis","year":"2016","journal-title":"PLoS One"},{"key":"2021122506422246900_R11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jamainternmed.2016.1709","article-title":"Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts","volume":"176","author":"Yeh","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2021122506422246900_R12","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/jamainternmed.2018.0776","article-title":"Pharmaceutical industry payments and oncologists\u2019 selection of targeted cancer therapies in Medicare beneficiaries","volume":"178","author":"Mitchell","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2021122506422246900_R13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.7326\/M14-1683","article-title":"Forecast for the Physician Payment Sunshine Act: Partly to mostly cloudy?","volume":"161","author":"Morain","year":"2014","journal-title":"Ann Intern Med"},{"key":"2021122506422246900_R14","author":"Hoadley","year":"2015"},{"key":"2021122506422246900_R15","author":"Medicare Provider Utilization and Payment Data","year":"2016"},{"key":"2021122506422246900_R16","author":"Physician Compare National Downloadable File"},{"key":"2021122506422246900_R17","author":"Responsibility of Applicants for Promoting Objectivity in Research for which PHS Funding is Sought","year":"2011"},{"key":"2021122506422246900_R18"},{"key":"2021122506422246900_R19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/ACM.0b013e3182087156","article-title":"Managing conflicts of interest in clinical care: A national survey of policies at U.S. medical schools","volume":"86","author":"Chimonas","year":"2011","journal-title":"Acad Med"},{"key":"2021122506422246900_R20","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0662","article-title":"Conflict of interest: An ethical firestorm with consequences for cancer research","author":"Chabner","year":"2018","journal-title":"The Oncologist"},{"key":"2021122506422246900_R21","article-title":"Leading US cancer hospital alters conflict of interest rules after controversies","volume":"363","author":"Dyer","year":"2018","journal-title":"BMJ"},{"key":"2021122506422246900_R22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2018.04.008","article-title":"The receipt of industry payments is associated with prescribing promoted alpha-blockers and overactive bladder medications","volume":"117","author":"Modi","year":"2018","journal-title":"Urology"},{"key":"2021122506422246900_R23","article-title":"Impact of industry payments on prescribing patterns for tumor necrosis factor inhibitors among Medicare beneficiaries","author":"Singh","year":"2018","journal-title":"J Gen Intern Med"},{"key":"2021122506422246900_R24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0194599818803337","article-title":"Industry payments to physicians and prescriptions of brand-name proton-pump inhibitors","volume":"160","author":"Morse","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2021122506422246900_R25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.urpr.2016.03.007","article-title":"The relationship of industry payments to prescribing behavior: A study of degarelix and denosumab","volume":"4","author":"Bandari","year":"2017","journal-title":"Urol Pract"},{"key":"2021122506422246900_R26","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/0194599818774739","article-title":"The association of industry payments to physicians with prescription of brand-name intranasal corticosteroids","volume":"159","author":"Morse","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2021122506422246900_R27","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1002\/cncr.30914","article-title":"The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide","volume":"123","author":"Bandari","year":"2017","journal-title":"Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0423","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/5\/632\/41921407\/oncolo_24_5_632.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/5\/632\/41921407\/oncolo_24_5_632.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:43:26Z","timestamp":1640414606000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/5\/632\/6439174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,2,6]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0423","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5,1]]},"published":{"date-parts":[[2019,2,6]]}}}